Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE44768 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) | |
US5362718 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5362718 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Aug, 2019
(4 years ago) | |
USRE44768 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Aug, 2019
(4 years ago) | |
US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(9 months ago) | |
US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(9 months ago) | |
US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(9 months ago) | |
US8455539 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(3 months ago) | |
US8299116 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(3 months ago) | |
US8722700 (Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(3 months ago) | |
US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(1 year, 8 months from now) | |
US8026276 (Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(2 years from now) | |
US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(8 years from now) | |
US8791097 (Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(8 years from now) |
Torisel is owned by Pf Prism Cv.
Torisel contains Temsirolimus.
Torisel has a total of 14 drug patents out of which 10 drug patents have expired.
Expired drug patents of Torisel are:
Torisel was authorised for market use on 30 May, 2007.
Torisel is available in solution;intravenous dosage forms.
Torisel can be used as method of treating metastatic papillary renal cell carcinoma with temsirolimus..
The generics of Torisel are possible to be released after 10 November, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-61) | May 30, 2015 |
M(M-92) | Jul 09, 2013 |
Orphan Drug Exclusivity(ODE) | May 30, 2014 |
M(M-91) | Apr 26, 2013 |
Pediatric Exclusivity(PED) | Jan 09, 2014 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS